Is Strong Q2 Results And Portfolio Shift Altering The Investment Case For Phibro Animal Health (PAHC)?
Phibro Animal Health reported strong fiscal Q2 2026 results, exceeding revenue and earnings expectations, and demonstrating improved profitability. The company's integration of Zoetis' medicated feed additive business and an expanding vaccines franchise are shifting its product mix towards higher-value items and broader international reach, potentially reshaping its investment narrative due to accelerating earnings and margin trends. While the outlook is positive, with revenue projected to reach $1.5 billion and earnings $119.1 million by 2028, investor caution is advised regarding its fair value and potential overreliance on medicated feed additives.
Insider Sale Tests Market View Of Phibro’s Growth And Valuation
BFI Co., LLC, an entity controlled by Phibro Animal Health’s CEO, recently executed a major insider share sale. This transaction follows strong operating results and expansion in the company's vaccine portfolio and international business. The article highlights that while analysts see the stock trading above target, Simply Wall St estimates it's significantly undervalued, raising questions about management's perception of current pricing.
BFI Co. sells $757k in Phibro Animal Health (PAHC) stock
BFI Co., LLC, a ten percent owner of Phibro Animal Health Corp (NASDAQ:PAHC), sold 14,080 shares of Class A Common Stock worth approximately $756,833. These sales occurred on March 30 and March 31, 2026, at prices between $53.5415 and $54.3533, following a 10b5-1 trading plan. Despite InvestingPro’s analysis suggesting PAHC is overvalued, the company recently reported strong fiscal Q2 2026 results, surpassing earnings and revenue forecasts.
Bendheim-linked BFI Co. LLC (PAHC) sells 14,080 shares under 10b5-1
BFI Co. LLC, an entity linked to Phibro Animal Health's President and CEO Jack Bendheim, sold 14,080 shares of Class A Common Stock (PAHC) on March 30 and March 31, 2026. These sales, executed under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, involved weighted average prices between $53.54 and $54.35 per share. Following these transactions, BFI Co. LLC indirectly holds 38,120 shares and Bendheim directly holds 16,840 shares, indicating a continued significant equity stake despite the sales.
Phibro Animal Health (PAHC) insider entity BFI Co. sells 21,120 shares
BFI Co., an entity linked to Phibro Animal Health (PAHC) President and CEO Jack Bendheim, sold 21,120 shares of Class A Common Stock between March 24–26, 2026. The sales were executed under a pre-scheduled Rule 10b5-1 trading plan at weighted average prices ranging from approximately $52.8772 to $57.1702 per share. Following these transactions, BFI Co. holds 52,200 Class A shares, and Jack Bendheim directly holds 16,840 shares.
Is Phibro Animal Health’s (PAHC) Efficiency Surge Quietly Rewriting Its Competitive Position in Animal Health?
Phibro Animal Health (PAHC) has demonstrated significant annual revenue growth of 21.7% and improved operating efficiency, which suggests it is gaining market share and enhancing profitability. The company's recent guidance for FY2026 projects net sales of US$1.45 billion to US$1.50 billion and net income of US$85 million to US$95 million, driven by better execution and integrated acquisitions. Despite these positive trends, the company's strong reliance on medicated feed additives may expose it to future regulatory or competitive pressures, which could impact the sustainability of its gains.
BFI Co sells Phibro Animal Health (PAHC) stock worth $1.19 million
BFI Co., LLC, a ten percent owner of Phibro Animal Health Corp (PAHC), sold 19,980 shares of Class A Common Stock for approximately $1.19 million between March 17 and March 19, 2026. The sales were conducted under a Rule 10b5-1 trading plan. Despite the sales, Phibro Animal Health reported strong fiscal Q2 2026 results, surpassing market expectations for both earnings per share and revenue.
BFI Co sells Phibro Animal Health (PAHC) stock worth $1.19 million By Investing.com
BFI Co., LLC, a significant owner of Phibro Animal Health Corp (PAHC), sold approximately $1.19 million worth of Class A Common Stock between March 17 and March 19, 2026, as part of a Rule 10b5-1 trading plan. Despite these sales near its 52-week high, Phibro Animal Health recently reported strong fiscal Q2 2026 results, surpassing revenue and EPS expectations. However, InvestingPro analysis suggests the stock might be overvalued with a P/E ratio of 23.42.
Phibro Animal Health (PAHC) CEO-linked BFI Co. sells 22,880 shares in Rule 10b5-1 trades
An entity linked to Phibro Animal Health's President and CEO, Jack Bendheim, BFI Co., LLC, sold 22,880 shares of Class A Common Stock between March 17 and 19, 2026. These sales, conducted under a Rule 10b5-1 trading plan, occurred at weighted average prices ranging from $51.6590 to $53.6436 per share. Following these transactions, BFI Co., LLC indirectly held 73,320 shares, while Jack Bendheim directly held 16,840 shares.
Phibro Insider Moves Shift Class Structure As Stock Trades Near Highs
Phibro Animal Health Corporation is experiencing shifts in its class structure as an insider, Jack Bendheim, sold Class A shares under a pre-arranged plan, and BFI Co., LLC converted Class B shares to Class A. These moves affect insider holdings, voting rights, and the mix of share classes, occurring as the stock trades near 52-week highs following strong fiscal Q2 2026 results. The article discusses potential implications for governance, liquidity, and investor sentiment, noting that while some see these as ordinary portfolio adjustments, they also signal a lean towards more institutional ownership and a slight reduction in super-voting stock power.
Phibro Animal Health (PAHC) director Bendheim sells $258,244 in shares By Investing.com
Phibro Animal Health (PAHC) director Jack Bendheim indirectly sold 5,280 Class A Common Stock shares for $258,244 on March 13, 2026, under a pre-arranged trading plan. Despite the sales, the stock has seen a significant 137% gain over the past year and recently reported strong fiscal Q2 2026 results, surpassing earnings and revenue expectations. InvestingPro analysis suggests the stock is currently overvalued.
Phibro Animal Health (PAHC) director Bendheim sells $258,244 in shares
Jack Bendheim, a director and CEO of Phibro Animal Health Corp (NASDAQ:PAHC), indirectly sold 5,280 shares of Class A Common Stock for $258,244 on March 13, 2026, under a pre-arranged trading plan. Despite sales, the stock has seen a 137% gain over the past year and recently reported strong fiscal Q2 2026 results, exceeding EPS and revenue expectations. InvestingPro analysis indicates PAHC is currently trading above its Fair Value.
Phibro Animal Health (PAHC) director Bendheim sells $258,244 in shares
Phibro Animal Health director Jack Bendheim indirectly sold 5,280 shares of Class A Common Stock for over $258,000 on March 13, 2026, through a pre-arranged trading plan. This transaction followed a conversion of Class B to Class A shares, leaving BFI Co., LLC with 96,200 Class A shares and Bendheim directly holding 16,840. The company recently reported strong fiscal Q2 2026 results, with earnings and revenue exceeding expectations, and its stock has seen a 137% gain over the past year.
BFI Co. tied to Phibro Animal Health (PAHC) converts and sells shares
BFI Co., LLC, an entity associated with Phibro Animal Health's President and CEO Jack Bendheim, converted 100,000 Class B shares into Class A shares and subsequently sold 5,280 Class A shares at a weighted average price of $48.91. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan. Despite the sale, BFI Co. and Jack Bendheim retain significant holdings in the company's Class A and Class B common stock.
A Look At Phibro Animal Health (PAHC) Valuation After A Strong 1 Year Total Return
Phibro Animal Health (PAHC) has seen a 135.9% total return over the past year, with revenues of US$1.46 billion and net income of US$92.09 million. While a popular narrative suggests the company is slightly overvalued at $48.50 due to non-repeatable growth drivers, a discounted cash flow model suggests it is significantly undervalued at $119.16. Investors are faced with conflicting valuation views, prompting a closer look at the company's future cash generation and growth prospects.
Multiple resale transactions by affiliate reported for Phibro Animal Health (PAHC)
Phibro Animal Health Corporation (PAHC) filed a Form 144, indicating proposed resale transactions of Class A Common Stock by its affiliate, BFI Co. LLC. The filing details multiple brokered sales from January to February 2026, including large single-day transactions. This routine disclosure provides transaction dates, share counts, and gross proceeds for the sales, but does not specify total registered shares or recipients of the proceeds.
A Look At Phibro Animal Health (PAHC) Valuation After Strong Q2 Beat And Higher Revenue Guidance
Phibro Animal Health (PAHC) significantly beat Q2 earnings and revenue expectations, leading to raised full-year revenue guidance. Despite strong recent share price performance and high returns, some analysts view the stock as overvalued at $54.54 against a fair value estimate of $48.50, attributing recent growth partly to non-repeatable synergies. However, a discounted cash flow model suggests the stock might be undervalued, trading 54.2% below an estimated $119.16, indicating divided sentiment on its true valuation.
Phibro Animal Health (PAHC) director sells $1.1 million in stock
A director and 10% owner of Phibro Animal Health (PAHC), Jack Bendheim and BFI Co., LLC, collectively sold $1.1 million worth of Class A Common Stock between February 24 and February 26, 2026. The sales were executed via a pre-arranged Rule 10b5-1 trading plan. This comes as the stock trades near its 52-week high, and an InvestingPro analysis suggests it is overvalued.
Phibro Animal Health (PAHC) CEO-linked LLC sells 21,120 shares
BFI Co., LLC, an entity associated with Phibro Animal Health Corp. (PAHC) President and CEO Jack Bendheim, sold a total of 21,120 shares of Class A common stock between February 24-26, 2026. These open-market transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted in May 2025, with weighted-average sale prices ranging from approximately $51 to $54 per share. The filing indicates some shares are held directly by Jack Bendheim, and others indirectly through BFI Co., LLC.
Phibro Animal Health (PAHC) director sells $1.1 million in stock By Investing.com
A director and a ten percent owner of Phibro Animal Health (PAHC), Jack Bendheim and BFI Co., LLC, collectively sold $1.1 million worth of Class A Common Stock between February 24 and February 26, 2026. The sales were executed through a pre-arranged trading plan as the stock traded near its 52-week high, and InvestingPro analysis suggests the stock is currently overvalued. Despite these insider sales, the company recently reported strong fiscal Q2 2026 results, significantly exceeding revenue and earnings per share forecasts.
Insider entity BFI Co. LLC trims Phibro Animal Health (PAHC) stake
BFI Co. LLC, an entity associated with Phibro Animal Health (PAHC) President and CEO Jack Bendheim, reported pre-planned sales of 14,080 shares of Class A Common Stock. These transactions were executed under a Rule 10b5-1 trading plan at weighted average prices between $50.2568 and $51.9644 per share. Following these sales, BFI Co. LLC holds 22,600 shares, while Jack Bendheim directly holds 16,840 shares.
Rule 10b5-1 sales by Phibro (PAHC) entity tied to CEO Bendheim
An entity linked to Phibro Animal Health's President and CEO, Jack Bendheim, sold 14,080 shares of Class A Common Stock of PAHC through Rule 10b5-1 trading plan. The sales by BFI Co., LLC occurred on February 13 and 18, 2026, at weighted average prices between $51 and $52 per share. Following these transactions, BFI Co., LLC retains 36,680 shares and Bendheim directly holds 16,840 shares.
Stronger Q2 Results And 2026 Outlook Might Change The Case For Investing In Phibro Animal Health (PAHC)
Phibro Animal Health (PAHC) reported strong Q2 2026 results with increased sales and net income, along with confident fiscal year 2026 guidance. This improved outlook provides a clearer view of the company's expected profitability, reinforcing its investment narrative amidst ongoing debates about its fair value and long-term margin sustainability. However, investors are cautioned about potential regulatory shifts and the differing analyst views on future performance.
Phibro Animal Health Corporation to Participate in Bank of America 2026 Virtual Animal Health Summit
Phibro Animal Health Corporation announced its participation in the Bank of America 2026 Virtual Animal Health Summit. Key executives will address financial analysts and investors on February 26, 2026. A live audio presentation will be available on the company's investor relations website, with a replay archived afterward.
BFI Co. sells 72,198 Phibro (PAHC) shares under 10b5-1 plan
BFI Co., LLC, an entity linked to Phibro Animal Health's CEO Jack Bendheim, sold 72,198 Class A common shares of Phibro (PAHC) on February 10-11, 2026. These sales were executed through a pre-arranged Rule 10b5-1 trading plan adopted in May 2025, with shares sold at weighted average prices between $51.61 and $52.21. After these transactions, BFI Co. retained 50,760 shares, while Jack Bendheim directly held 16,840 shares.
Form 4: David Glenn reports acquisition/exercise transactions in PAHC
David Glenn, CFO of Phibro Animal Health Corp (PAHC), reported acquisition and exercise transactions in a recent Form 4 filing. The transactions involved the exercise of 30,000 restricted stock units (RSUs) into Class A Common Stock and a subsequent sale of 12,528 shares at a weighted average price of $51.625 to cover tax withholding obligations. Following these transactions, Glenn directly holds 52,317 shares of PAHC and beneficially owns 240,000 RSUs.
Assessing Phibro Animal Health (PAHC) Valuation After Strong Q2 Results And Higher 2026 Earnings Guidance
Phibro Animal Health (PAHC) recently reported strong Q2 results and updated 2026 earnings guidance, leading to a significant increase in its share price. While one narrative suggests the stock is overvalued at $51.85 compared to a $43 fair value, pointing to non-repeatable growth drivers, a discounted cash flow (DCF) model indicates a deep value with a fair value of $119.16. The article encourages investors to analyze different valuation perspectives and consider additional research through various stock screeners.
Why Phibro Animal Health (PAHC) Is Up 32.2% After Raising FY26 Guidance On Animal Health Strength
Phibro Animal Health (PAHC) recently reported strong second-quarter results, with sales rising to US$373.91 million and net income reaching US$27.46 million. This performance led to a raised fiscal 2026 guidance of US$1.45–1.50 billion in net sales and US$85–95 million in net income, primarily driven by the strength of its Animal Health segment. While the company's shares have surged, the investment narrative includes considerations like acquisition integration, margin pressures, leverage, valuation, and recent insider selling.
Phibro Animal Health Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Phibro Animal Health Corporation (NASDAQ:PAHC) recently reported strong second-quarter results, with revenues exceeding expectations and statutory profit significantly higher than forecasts. Following these positive results, analysts have raised their earnings per share expectations for 2026 and increased the consensus price target for the stock, signaling a more bullish outlook despite predictions of slower revenue growth compared to the broader industry.
Phibro Animal Health (PAHC) Margin Rebound And EPS Surge Test Cautious Growth Narratives
Phibro Animal Health (PAHC) reported strong Q2 2026 results with significant revenue and EPS growth, challenging previous cautious growth narratives despite lower forecast growth compared to the broader US market. The company saw a rebound in net margin to 6.3% but faces mixed valuation signals and concerns about debt coverage by operating cash flow. Investors are evaluating the recent performance against long-term trends and balance sheet risks.
Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
Phibro Animal Health Corporation reported strong second-quarter results for the period ended December 31, 2025, with net sales increasing by 21% to $373.9 million and diluted EPS rising to $0.67. The company's Animal Health segment saw significant growth, partly due to the recent MFA portfolio acquisition. Based on this performance, Phibro has raised its financial guidance for fiscal year 2026, projecting net sales between $1.45 billion and $1.50 billion and Adjusted EBITDA between $245 million and $255 million.
Phibro Animal Health Declares Quarterly Cash Dividend
Phibro Animal Health (PAHC) has declared a quarterly cash dividend of $0.12 per share for both Class A and Class B common stock, payable on March 25, 2026, to shareholders of record as of March 4, 2026. This decision reflects the company's commitment to returning capital and confidence in its financial health. Despite a "Sell" rating from one analyst with a $32.00 price target, TipRanks' AI Analyst, Spark, assesses PAHC as "Neutral" due to strong earnings and increased guidance, balanced by concerns over high leverage and negative cash flow growth.
Phibro Animal Health Declares Quarterly Cash Dividend
Phibro Animal Health (PAHC) has declared a quarterly cash dividend of $0.12 per share for both its Class A and Class B common stock. This dividend is payable on March 25, 2026, to shareholders of record as of March 4, 2026, signaling the company's commitment to returning capital and confidence in its financial health. While an analyst maintains a "Sell" rating with a $32.00 price target, TipRanks' AI Analyst, Spark, rates PAHC as "Neutral" due to strong earnings and increased guidance, despite financial risks like high leverage and negative cash flow growth.
Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation (Nasdaq: PAHC) announced a quarterly cash dividend of $0.12 per share for its Class A and Class B common stock. The dividend is payable on March 25, 2026, to stockholders of record as of March 4, 2026. Phibro Animal Health Corporation is a global diversified animal health and nutrition company.
Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.12 per share for its Class A and Class B common stock. This dividend is payable on March 25, 2026, to stockholders of record as of March 4, 2026. Phibro Animal Health Corporation is a global diversified animal health and nutrition company.
Phibro Animal Health Corporation to Host Webcast and Conference Call on Second Quarter Results
Phibro Animal Health Corporation announced it will release its second-quarter financial results on Wednesday, February 4, 2026, after market close. Management will host a conference call and webcast on Thursday, February 5, 2026, at 9:00 AM ET to discuss these results. Interested parties can access the webcast and presentation slides via the company's investor relations website or by dialing into the conference call.
Lobbying Update: $30,000 of PHIBRO ANIMAL HEALTH CORPORATION lobbying was just disclosed
PHIBRO ANIMAL HEALTH CORPORATION (PAHC) disclosed $30,000 in lobbying expenditures for Q4 2025, primarily focused on advocating for pig disease medicines. The article also details recent insider trading activity, showing significant sales by the CEO, and varying hedge fund sentiment with some funds adding and others decreasing their positions. Analyst ratings are split between "Overweight" and "Underperform," with a median price target of $38.5.
Phibro announces quarterly dividend of $0.12 per share
Phibro Animal Health Corporation announced a quarterly dividend of $0.12 per share for holders of its Class A common stock. This dividend is payable on March 27, 2026, to stockholders of record as of February 27, 2026. This announcement reflects the company's regular distribution policy to its shareholders.
Phibro Animal Health (PAHC) director sells $569k in shares By Investing.com
A director at Phibro Animal Health (PAHC), Jack Bendheim, and BFI Co., LLC, a ten-percent owner, sold shares totaling $569,753 between January 13 and January 15, 2026. These sales were executed under a pre-arranged Rule 10b5-1 trading plan. The company's stock has seen significant growth, returning 95% over the past year, and analysts anticipate further growth in net income.
BFI Co sells Phibro Animal Health (PAHC) shares for $8554 By Investing.com
BFI Co., LLC, a significant shareholder in Phibro Animal Health Corp (NASDAQ:PAHC), sold 213 shares of Class A Common Stock for $8,554 on January 9, 2026. This transaction follows a remarkable 102.81% return for PAHC shares over the past year. The sale was executed under a Rule 10b5-1 trading plan, and the company has recently reported strong quarterly results and announced a leadership transition.
Phibro Animal Health (PAHC) director sells $569k in shares
A director of Phibro Animal Health (PAHC), Jack Bendheim, and BFI Co., LLC, a ten-percent owner, sold shares of the company totaling $569,753 between January 13 and January 15, 2026, at prices ranging from $40.0233 to $41.1375. These sales were executed under a pre-arranged Rule 10b5-1 trading plan. Despite the insider selling, Phibro Animal Health has shown strong performance with a 95% return over the past year and a "GREAT" financial health score, with analysts setting price targets between $32 and $50.
BFI Co sells Phibro Animal Health (PAHC) shares for $8554 By Investing.com
BFI Co., LLC, a significant owner of Phibro Animal Health Corp (PAHC), sold 213 shares for $8,554 on January 9, 2026, through a Rule 10b5-1 trading plan. This transaction occurred amidst a strong performance for PAHC shares, which saw a 102.81% return over the past year, though InvestingPro suggests the stock is currently trading above its Fair Value. The sale highlights insider activity as the company also recently reported strong Q1 fiscal year 2026 results and announced a leadership transition.
Phibro Animal Health (PAHC) director sells $569k in shares By Investing.com
A director of Phibro Animal Health (PAHC), Jack Bendheim, and BFI Co., LLC, a significant owner, sold shares totaling $569,753 between January 13 and January 15, 2026, using a pre-arranged trading plan. Despite these sales, the company stock has seen a 95% return over the past year and analysts expect net income growth. Phibro also reported strong Q1 fiscal year 2026 results and announced a CEO transition for July 2026.
Phibro Animal Health (PAHC) director sells $569k in shares
Phibro Animal Health director Jack Bendheim and BFI Co., LLC, a ten-percent owner, sold shares worth $569,753 between January 13 and January 15, 2026, under a pre-arranged trading plan. The sales occurred at prices ranging from $40.0233 to $41.1375, with the stock currently trading at $40.04 and having a 95% return over the past year. Phibro Animal Health has a "GREAT" financial health score and is expected to grow net income this year, with upcoming earnings on February 11 and a CEO transition in July 2026.
Phibro Animal Health (PAHC) director sells $569k in shares
A director and ten-percent owner of Phibro Animal Health (PAHC), Jack Bendheim and BFI Co., LLC, collectively sold shares worth $569,753 between January 13 and January 15, 2026. These sales were executed under a pre-arranged trading plan, while the company's stock has shown a 95% return over the past year. Phibro Animal Health is expected to report strong earnings and maintain a "GREAT" financial health score according to InvestingPro analysis, despite BofA Securities maintaining an Underperform rating.
Phibro Animal Health (PAHC) director sells $569k in shares
A director at Phibro Animal Health (PAHC), Jack Bendheim, and BFI Co., LLC, a major shareholder, sold a total of $569,753 worth of shares between January 13 and January 15, 2026. These sales were conducted under a pre-arranged trading plan, with share prices ranging from $40.0233 to $41.1375. The company recently reported strong Q1 fiscal year 2026 results, surpassing analyst expectations, and is preparing for a CEO transition in July 2026.
A Look At Phibro Animal Health (PAHC) Valuation After Strong Recent Shareholder Returns
Phibro Animal Health (PAHC) has seen strong shareholder returns and is currently trading at US$39.72. While a narrative fair value suggests it's 7.6% undervalued at around US$43, its P/E ratio of 23.7x is higher than the industry average, implying investors are paying a premium. This article explores the valuation and discusses factors influencing its future growth and potential risks.
BFI Co sells Phibro Animal Health (PAHC) shares for $8554
BFI Co., LLC, a significant owner of Phibro Animal Health Corp (PAHC), sold 213 shares of Class A Common Stock for $8554 on January 9, 2026, as part of a pre-planned trading strategy. This transaction follows a strong performance for PAHC shares over the past year and occurred while the stock traded above its InvestingPro Fair Value. The article also notes PAHC's recent positive financial results, leadership transition, and an increased price target from BofA Securities despite an "Underperform" rating.
BFI Co sells Phibro Animal Health (PAHC) shares for $8554 By Investing.com
BFI Co., LLC, a ten percent owner of Phibro Animal Health Corp (NASDAQ:PAHC), sold 213 shares of Class A Common Stock for $8,554. The sale was executed on January 9, 2026, at $40.16 per share, following a significant 102.81% return for PAHC shares over the past year. The company recently reported strong Q1 fiscal year 2026 results and is undergoing a leadership transition.
BFI Co sells Phibro Animal Health (PAHC) shares for $8554
BFI Co., LLC, a ten percent owner of Phibro Animal Health Corp (NASDAQ:PAHC), sold 213 shares of Class A Common Stock for $8,554 on January 9, 2026. This transaction follows a significant 102.81% return for PAHC shares over the past year and occurred under a Rule 10b5-1 trading plan. Despite the stock trading above its Fair Value according to InvestingPro, the company recently reported strong Q1 fiscal year 2026 results and announced a leadership transition plan.
